Literature DB >> 32386314

Survival outcomes of patients with high-grade and poorly differentiated thymic neuroendocrine carcinoma.

Masatsugu Hamaji1, Mitsugu Omasa2, Tatsuo Nakagawa3, So Miyahara4, Michiharu Suga5, Kenzo Kawakami6, Akihiro Aoyama7, Hiroshi Date1.   

Abstract

High-grade and poorly differentiated thymic neuroendocrine carcinoma is the rarest entity in thymic epithelial tumours. The aim of this study is to report survival data in a multi-institutional database in comparison to data in the literature. Retrospective chart review was performed on the basis of our multi-institutional database to identify patients undergoing the resection of poorly differentiated thymic neuroendocrine carcinoma between 1991 and 2018. Relevant factors were extracted, and survival analysis was performed using the Kaplan-Meier method. Twenty-one patients were identified. Five-year overall survival and recurrence-free survival were 64.6% and 51.8%, respectively. Twelve (57.1%) patients had recurrences. Due to the scarcity of data reported in the literature, our data may be used as a standard in high-grade and poorly differentiated thymic neuroendocrine carcinoma.
© The Author(s) 2020. Published by Oxford University Press on behalf of the European Association for Cardio-Thoracic Surgery. All rights reserved.

Entities:  

Keywords:  Carcinoma; Neuroendocrine; Survival; Thymic

Mesh:

Year:  2020        PMID: 32386314     DOI: 10.1093/icvts/ivaa059

Source DB:  PubMed          Journal:  Interact Cardiovasc Thorac Surg        ISSN: 1569-9285


  2 in total

1.  A Single Center Analysis of Thymic Neuroendocrine Tumors.

Authors:  Yirui Zhai; Qiang Zeng; Nan Bi; Zongmei Zhou; Zefen Xiao; Zhouguang Hui; Dongfu Chen; Luhua Wang; Jianyang Wang; Wenyang Liu; Lei Deng; Jima Lv; Wenqing Wang; Yang Luo; Junling Li; Xin Wang; Tao Zhang; Yushun Gao; Qinfu Feng
Journal:  Cancers (Basel)       Date:  2022-10-09       Impact factor: 6.575

2.  Clinical Significance of Tumor Markers for Advanced Thymic Carcinoma: A Retrospective Analysis from the NEJ023 Study.

Authors:  Tomoyasu Mimori; Takehito Shukuya; Ryo Ko; Yusuke Okuma; Tomonobu Koizumi; Hisao Imai; Yuichi Takiguchi; Eisaku Miyauchi; Hiroshi Kagamu; Tomohide Sugiyama; Keisuke Azuma; Yukiko Namba; Masahiro Yamasaki; Hisashi Tanaka; Yuta Takashima; Sayo Soda; Osamu Ishimoto; Nobuyuki Koyama; Kunihiko Kobayashi; Kazuhisa Takahashi
Journal:  Cancers (Basel)       Date:  2022-01-11       Impact factor: 6.639

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.